scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1020093504 |
P356 | DOI | 10.1007/BF03256640 |
P698 | PubMed publication ID | 14720023 |
P2093 | author name string | Joan B Soriano | |
Jørgen Vestbo | |||
Victor A Kiri | |||
Neil B Pride | |||
P433 | issue | 1 | |
P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
P304 | page(s) | 67-74 | |
P577 | publication date | 2003-01-01 | |
P1433 | published in | Treatments in Respiratory Medicine | Q15755236 |
P1476 | title | Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients | |
P478 | volume | 2 |
Q46476422 | A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination |
Q37018812 | Changing the burden of COPD mortality |
Q91624819 | Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease |
Q37017520 | Comparison and optimal use of fixed combinations in the management of COPD. |
Q43884681 | Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population |
Q36135425 | Differences in COPD-related readmissions to primary and secondary care hospitals |
Q52949846 | Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. |
Q37785279 | Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease |
Q36255228 | Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidence |
Q51599981 | Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. |
Q34252132 | Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation |
Q37017524 | Genetic predisposition to accelerated decline of lung function in COPD |
Q37532050 | Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. |
Q34065276 | Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective |
Q35871163 | Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease |
Q36815073 | Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? |
Q34691221 | Markers of exacerbation severity in chronic obstructive pulmonary disease |
Q36742804 | Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena |
Q35834324 | Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease |
Q37336771 | Optimising treatment for COPD--new strategies for combination therapy |
Q36859405 | Optimizing economic outcomes in the management of COPD. |
Q95264388 | Predicting and preventing hospital readmission for exacerbations of COPD |
Q37018817 | Salmeterol/fluticasone combination in the treatment of COPD. |
Q36993392 | Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease |
Q36779343 | Tackling COPD: a multicomponent disease driven by inflammation |
Q37748948 | The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease |
Q33966009 | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. |
Q60302185 | Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: Impact on mortality |
Q80190969 | [Contribution of cohort studies on exacerbations and their management] |
Search more.